NCT07316309Completed
CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer
A Prospective Study of [18F]AlF-NOTA-QHY-04 PET/CT for Predicting Outcome in Patients With Limited-Stage Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC). Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker. The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 33 (actual)
- First submitted
- 18 Dec 2025
- Start date
- 28 Nov 2022
- Primary completion date
- 19 Jul 2024
- Lead sponsor
- Shandong Cancer Hospital and Institute
- Diseases
- Lung cancer
- NCT number
- NCT07316309
What you commit to
- Study type: Observational
- Participants enrolled: 33
- From 28 Nov 2022 to the primary completion date, 19 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of autoimmune diseases or active comorbid infections.
Other
- Pregnancy or breastfeeding.
- Unable or unwilling to provide informed consent.
Who the study is looking for
- Histopathologically confirmed limited-stage small cell lung cancer (T1-4N0-3M0) according to the AJCC TNM 8th edition.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Presence of measurable disease according to RECIST version 1.1.
- Newly diagnosed patients who had not received any prior anticancer treatment.
- Underwent baseline \[18F\]AlF-NOTA-QHY-04 PET/CT imaging prior to treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shandong Cancer Hospital and Institute Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.